Association of PARP1 SNP (rs1136410) with Brain Tumor Risk: Insights from Khyber Pakhtunkhwa
- 1Department of Biotechnology, Faculty of Chemical and Life Sciences, Abdul Wali Khan University Mardan, Pakistan.
- 2Gastro Ward, Hayatabad Medical Complex, Peshawar, Pakistan.
- 3Peshawar General Hospital, Peshawar, Pakistan.
Abstract
Background:: Brain tumors are among the most complex and life-threatening malignancies, with limited understanding of their genetic etiology. Poly (ADP-ribose) polymerase 1 (PARP1) plays a critical role in DNA repair. The single nucleotide polymorphism (SNP) rs1136410 (A>G) in PARP1, which results in a Val762Ala substitution, has been suggested to alter PARP1 enzymatic activity and potentially influence tumor development. However, its association with brain tumors remains underexplored particularly in the population of Khyber Pakhtunkhwa (KP), Pakistan.
Methods:: In this study, we enrolled 200 patients with brain tumors, along with an additional 200 individuals as controls. DNA was extracted using the phenol–chloroform method, followed by genotyping through the Amplification Refractory Mutation System–Polymerase Chain Reaction (ARMS-PCR). Statistical analysis was conducted using GraphPad Prism.
Results:: The genotypic distribution of rs1136410 in brain tumor patients and healthy individuals indicates that this SNP is significantly associated with brain tumors (Chi-square = 13.24, df = 2, p = 0.0013). The AA genotype was associated with a 77% increased risk of overall brain tumors (OR = 1.77, p = 0.0065), an 88% increased risk of glioma (OR = 1.88, p = 0.0159), and a 2.9-fold increased risk of meningioma (OR = 2.91, p = 0.0073). In contrast, the GG genotype was associated with a 63% decreased risk of overall brain tumors (OR = 0.37, p = 0.0011), an 84% decreased risk of glioma (OR = 0.26, p = 0.0019), and an 80% decreased risk of meningioma (OR = 0.21, p = 0.0217). Similarly, the A allele was associated with an increased risk of brain tumors (OR = 1.88, p = 0.0065), whereas the G allele was associated with a decreased risk (OR = 0.53, p = 0.0001).
Conclusion:: In conclusion, this study demonstrates that rs1136410 is significantly associated with brain tumor risk particularly with the glioma and meningioma subtypes underscoring the role of PARP1 in brain tumor genetics and its potential as a therapeutic target.
Related
- Embedding cognitive behavioural therapy for depression among patients with tuberculosis in Khyber Pakhtunkhwa, Pakistan: insights from a pilot trial process evaluation
- Molecular characterization of carbapenemase-producing Enterobacterales from Peshawar City, Khyber Pakhtunkhwa, Pakistan.
- Whole-genome analysis of drug resistance and transmission patterns in Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan
- Exploring enablers and barriers for implementing community-based surveillance strengthening early detection and response in District Mardan Khyber Pakhtunkhwa Pakistan
- Social protection and climate resilience among informal workers in Pakistan: a qualitative study of the Benazir income support programme in Khyber Pakhtunkhwa.
BibTeX
@article{gul2026association,
title = {{Association of PARP1 SNP (rs1136410) with Brain Tumor Risk: Insights from Khyber Pakhtunkhwa}},
author = {Sajjad Gul and Sajid Ali and Muhammad Nouman and Adnan ur Rehman and Sana Khan and Sumbal Hussain and Shaista Afzal and Hamid Ali and Muhammad Ashraf and Naveed Anwar},
journal = {Asian Pacific Journal of Cancer Prevention : APJCP},
year = {2026},
month = jun,
doi = {10.31557/apjcp.2026.27.6.1997},
url = {https://doi.org/10.31557/apjcp.2026.27.6.1997},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Association of PARP1 SNP (rs1136410) with Brain Tumor Risk: Insights from Khyber Pakhtunkhwa
AU - Sajjad Gul
AU - Sajid Ali
AU - Muhammad Nouman
AU - Adnan ur Rehman
AU - Sana Khan
AU - Sumbal Hussain
AU - Shaista Afzal
AU - Hamid Ali
AU - Muhammad Ashraf
AU - Naveed Anwar
PY - 2026
DA - 2026/06/18
JO - Asian Pacific Journal of Cancer Prevention : APJCP
DO - 10.31557/apjcp.2026.27.6.1997
UR - https://doi.org/10.31557/apjcp.2026.27.6.1997
AB - Background:: Brain tumors are among the most complex and life-threatening malignancies, with limited understanding of their genetic etiology. Poly (ADP-ribose) polymerase 1 (PARP1) plays a critical role in DNA repair. The single nucleotide polymorphism (SNP) rs1136410 (A>G) in PARP1, which results in a Val762Ala substitution, has been suggested to alter PARP1 enzymatic activity and potentially influence tumor development. However, its association with brain tumors remains underexplored particularly in the population of Khyber Pakhtunkhwa (KP), Pakistan. Methods:: In this study, we enrolled 200 patients with brain tumors, along with an additional 200 individuals as controls. DNA was extracted using the phenol–chloroform method, followed by genotyping through the Amplification Refractory Mutation System–Polymerase Chain Reaction (ARMS-PCR). Statistical analysis was conducted using GraphPad Prism. Results:: The genotypic distribution of rs1136410 in brain tumor patients and healthy individuals indicates that this SNP is significantly associated with brain tumors (Chi-square = 13.24, df = 2, p = 0.0013). The AA genotype was associated with a 77% increased risk of overall brain tumors (OR = 1.77, p = 0.0065), an 88% increased risk of glioma (OR = 1.88, p = 0.0159), and a 2.9-fold increased risk of meningioma (OR = 2.91, p = 0.0073). In contrast, the GG genotype was associated with a 63% decreased risk of overall brain tumors (OR = 0.37, p = 0.0011), an 84% decreased risk of glioma (OR = 0.26, p = 0.0019), and an 80% decreased risk of meningioma (OR = 0.21, p = 0.0217). Similarly, the A allele was associated with an increased risk of brain tumors (OR = 1.88, p = 0.0065), whereas the G allele was associated with a decreased risk (OR = 0.53, p = 0.0001). Conclusion:: In conclusion, this study demonstrates that rs1136410 is significantly associated with brain tumor risk particularly with the glioma and meningioma subtypes underscoring the role of PARP1 in brain tumor genetics and its potential as a therapeutic target.
SN - 1513-7368
SN - 2476-762X
ER -